Experimental combo targets stomach cancer fluid after other treatments fail
NCT ID NCT07196540
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study tests a three-part treatment for people with advanced digestive tract cancers that have caused fluid buildup in the belly (malignant ascites) and haven't responded to standard therapies. The treatment combines low-dose radiation to the abdomen with two injected drugs: a modified tumor necrosis factor and an immunotherapy called tislelizumab. The goal is to see if this combination can shrink or stop the fluid buildup, and how safe it is. About 78 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE SYSTEM NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant modified human tumor necrosis factor (rmhTNF-NC) combined with tislelizumab and radiotherapy
What this could lead to
If successful, this could offer a new treatment option for people with advanced digestive tract cancers who have run out of standard therapies and are suffering from fluid buildup in the abdomen.
What could go wrong
This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. The combination therapy may cause side effects like inflammation or organ damage, and it's not yet known if it will meaningfully extend life or just temporarily reduce fluid.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.